Literature DB >> 31410680

Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence.

Chi Peng Timothy Lai1, Joe Poh Sheng Yeong2,3, An Sen Tan1, Chong Hui Clara Ong2, Bernett Lee3, Jeffrey Chun Tatt Lim2,4, Aye Aye Thike2, Jabed Iqbal2,5, Rebecca Alexandra Dent6, Elaine Hsuen Lim6, Puay Hoon Tan7,8.   

Abstract

PURPOSE: We used multiplex immunofluorescence (mIF) to determine whether mitotic rate represents an independent prognostic marker in triple-negative breast cancer (TNBC). Secondary aims were to confirm the prognostic significance of immune cells in TNBC, and to investigate the relationship between immune cells and proliferating tumour cells.
METHODS: A retrospective Asian cohort of 298 patients with TNBC diagnosed from 2003 to 2015 at the Singapore General Hospital was used in the present study. Formalin-fixed, paraffin-embedded breast cancer samples were analysed on tissue microarrays using mIF, which combined phospho-histone H3 (pHH3) expression with cytokeratin (CK) and leukocyte common antigen (CD45) expression to identify tumour and immune cells, respectively.
RESULTS: Multivariate analysis showed that a high pHH3 index was associated with significantly improved overall survival (OS; p = 0.004), but this was not significantly associated with disease-free survival (DFS; p = 0.22). Similarly, multivariate analysis also revealed that a pHH3 positive count of > 1 cell per high-power field in the malignant epithelial compartment was an independent favourable prognostic marker for OS (p = 0.033) but not for DFS (p = 0.250). Furthermore, a high CD45 index was an independent favourable prognostic marker for DFS (p = 0.018), and there was a significant positive correlation between CD45 and pHH3 index (Spearman rank correlation coefficient, 0.250; p < 0.001).
CONCLUSIONS: Mitotic rates as determined by pHH3 expression in epithelial cells are significantly associated with improved survival in TNBC. mIF analysis of pHH3 in combination with CK and CD45 could help clinicians in prognosticating patients with TNBC.

Entities:  

Keywords:  Breast cancer; Immune; Prognosis; Proliferation; TNBC; pHH3

Mesh:

Substances:

Year:  2019        PMID: 31410680     DOI: 10.1007/s10549-019-05396-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  4 in total

1.  Inhibition of Cdc20 suppresses the metastasis in triple negative breast cancer (TNBC).

Authors:  Christine Song; Val J Lowe; SeungBaek Lee
Journal:  Breast Cancer       Date:  2021-04-03       Impact factor: 4.239

2.  Tsc2 mutation induces renal tubular cell nonautonomous disease.

Authors:  Prashant Kumar; Fahad Zadjali; Ying Yao; Daniel Johnson; Brian Siroky; Aristotelis Astrinidis; Peter Vogel; Kenneth W Gross; John J Bissler
Journal:  Genes Dis       Date:  2021-04-27

3.  The value of Phosphohistone H3 as a cell proliferation marker in oral squamous cell carcinoma. A comparative study with Ki-67 and the mitotic activity index.

Authors:  N Tancredi-Cueto; G Vigil-Bastitta; R Bologna-Molina; V Beovide-Cortegoso
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2022-09-01

4.  Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.

Authors:  Harry Ho Man Ng; Ren Yuan Lee; Siting Goh; Isabel Shu Ying Tay; Xinru Lim; Bernett Lee; Valerie Chew; Huihua Li; Benedict Tan; Sherlly Lim; Jeffrey Chun Tatt Lim; Bijin Au; Josh Jie Hua Loh; Sahil Saraf; John Edward Connolly; Tracy Loh; Wei Qiang Leow; Joycelyn Jie Xin Lee; Han Chong Toh; Fabio Malavasi; Ser Yee Lee; Pierce Chow; Evan W Newell; Su Pin Choo; David Tai; Joe Yeong; Tony Kiat Hon Lim
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.